Journal Article10.1002/CCD.25946
Renal frame count: a measure of renal flow that predicts success of renal artery stenting in hypertensive patients.
19
TL;DR: The role of the renal frame count (RFC) (number of angiographic frames for contrast to reach distal renal parenchyma after initial RA opacification) as a predictor of improvement in blood pressure (BP) after RA stenting is determined.
read more
Abstract: Objectives
Renal artery (RA) stenting can improve control of hypertension yet predicting clinical response remains difficult. We sought to determine the role of the renal frame count (RFC) (number of angiographic frames for contrast to reach distal renal parenchyma after initial RA opacification) as a predictor of improvement in blood pressure (BP) after RA stenting.
Methods
Renal flow was quantified in 68 consecutive patients (age 72.5 ± 9.1 years, 72% male) undergoing RA stenting for refractory hypertension (BP ≥ 140/90 mm Hg despite treatment with two or more antihypertensive medications) by measuring RFC pre-RA stenting. Significant renal artery stenosis (RAS) was defined as a stenosis ≥ 70% by visual estimation on angiography. Baseline and 6-month follow-up BP was recorded. Clinical response was defined by a drop in systolic blood pressure (SBP) >10 mm Hg on the same or fewer number of anti-hypertensive medications.
Results
Patients with RFC > 30 had SBP reduction (43.2 ± 25.7 mm Hg vs. 30.1 ± 31.3 mm Hg, P = 0.067), diastolic blood pressure reduction (9.1 ± 19.0 vs. −0.2 ± 13.4 mm Hg, P = 0.02), and mean arterial pressure reduction (23.8 ± 19.4 vs. 11.8 ± 16.1 mm Hg, P 30 was associated with a higher rate of clinical response to RA stenting (93.5% vs. 73%, P = 0.027).
Conclusions
RFC can be used as a clinical predictor of response to RA stenting. RFC > 30 was associated with reduction in BP after RA stenting and was predictive of clinical response. RFC provides a useful intraprocedural tool in assessing the severity of RAS and predicts the likelihood of clinical response following RA stenting. © 2015 Wiley Periodicals, Inc.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
When and How Should We Revascularize Patients With Atherosclerotic Renal Artery Stenosis
TL;DR: Techniques to optimize patient selection, to minimize procedural complications, and to facilitate durable patency of renal stenting are reviewed and the current American College of Cardiology and American Heart Association guidelines and the Society for Cardiovascular Angiography and Interventions appropriate use criteria are reviewed.
104
Evaluation of the Safety and Effectiveness of Renal Artery Stenting After Unsuccessful Balloon Angioplasty: The ASPIRE-2 Study
TL;DR: In hypertensive patients with aorto-ostial atherosclerotic renal artery stenosis in whom PTRA is unsuccessful, Palmaz (Cordis Corp., Warren, New Jersey) balloon-expandable stents provide a safe and durable revascularization strategy, with a beneficial impact on hypertension.
101
Renal Artery Stenosis: When to Revascularize in 2017.
TL;DR: Patients with uncontrolled renovascular hypertension despite optimal medical therapy, ischemic nephropathy, and cardiac destabilization syndromes who have severe renal artery stenosis are likely to benefit from renal artery revascularization.
34
Renal Artery Stenosis in the Patient with Hypertension: Prevalence, Impact and Management.
Rohini Manaktala,Jose D Tafur-Soto,Christopher J. White +2 more
- 02 Jun 2020
TL;DR: Renal revascularization with PTRAS provides a survival advantage in individuals with significant hemodynamic renal artery stenosis lesions and it is important that it is screen, diagnosis, intervene with invasive and medical treatments appropriately in these high-risk patients.
References
Revascularization versus medical therapy for renal-artery stenosis.
Keith Wheatley,Natalie Ives,Richard Gray,Philip A. Kalra,Jonathan Moss,Colin Baigent,Sue Carr,Nicholas Chalmers,D Eadington,George Hamilton,G Lipkin,Anthony A. Nicholson,J Scoble +12 more
TL;DR: It is found that substantial risks are found but no evidence of a worthwhile clinical benefit from revascularization in patients with atherosclerotic renovascular disease.
Renal-Artery Stenosis
TL;DR: The goals for treating patients with RAS are to reduce cardiovascu-lar morbidity and mortality attributable to elevated arterial pressure and to preserve renal function beyond critical stenosis and to identify progressive occlusive disease and to determine appropriate timing for vascular intervention.
1K
Stenting and medical therapy for atherosclerotic renal-artery stenosis
Christopher J. Cooper,Timothy P. Murphy,Donald E. Cutlip,Kenneth Jamerson,William L. Henrich,Diane M. Reid,David J. Cohen,Alan H. Matsumoto,Michael W. Steffes,Michael R. Jaff,Martin R. Prince,Eldrin F. Lewis,Katherine R. Tuttle,Joseph I. Shapiro,John H. Rundback,Joseph M. Massaro,Lance D. Dworkin +16 more
TL;DR: Renal-artery stenting did not confer a significant benefit with respect to the prevention of clinical events when added to comprehensive, multifactorial medical therapy in people with atherosclerotic renal-arterY stenosis and hypertension or chronic kidney disease.
Renal artery stenosis.
TL;DR: Despite the lack of sufficiently powered randomized controlled trials, each hemodynamically relevant RAS should be considered for stent angioplasty in patients without end-stage ischemic nephropathy or limited life expectancy due to concomitant disease (eg, cancer).
428
Related Papers (5)
Christopher J. Cooper,Timothy P. Murphy,Donald E. Cutlip,Kenneth Jamerson,William L. Henrich,Diane M. Reid,David J. Cohen,Alan H. Matsumoto,Michael W. Steffes,Michael R. Jaff,Martin R. Prince,Eldrin F. Lewis,Katherine R. Tuttle,Joseph I. Shapiro,John H. Rundback,Joseph M. Massaro,Lance D. Dworkin +16 more
Liesbeth Bax,A J Woittiez,Hans J. Kouwenberg,Willem P.Th.M. Mali,Erik Buskens,Frederik J. A. Beek,Branko Braam,F.T.M. Huysmans,Leo J. Schultze Kool,Matthieu J. C. M. Rutten,Cornelius J. Doorenbos,Johannes C. N. M. Aarts,Ton J. Rabelink,Pierre-François Plouin,Alain Raynaud,Gert A. van Montfrans,Jim A. Reekers,Anton H. van den Meiracker,Peter M. T. Pattynama,Peter J.G. van de Ven,Dammis Vroegindeweij,Abraham A. Kroon,Michiel W. de Haan,Cornelis T. Postma,Jaap J. Beutler +24 more